Lv5
820 积分 2025-05-16 加入
The Courage study: A first-in-human phase 1 study of the CBP/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer
16天前
已完结
TT125-802, a highly selective, well-tolerated bromodomain inhibitor of CBP/p300 with anti-tumor activity in patients with advanced solid tumors: An update on the ongoing phase I study
16天前
已关闭
Activity of NEO2734, a novel dual inhibitor of both BET and CBP-P300, in SPOP-mutated prostate cancer
16天前
已关闭
The Courage study: A first-in-human phase 1 study of the CBP/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer
16天前
已完结
CCS1477, a Novel p300/CBP Bromodomain Inhibitor, Enhances Efficacy of Azacitidine and Venetoclax in Pre-Clinical Models of Acute Myeloid Leukaemia and Lymphoma
16天前
已关闭
Structural insights revealed by the cocrystal structure of CCS1477 in complex with CBP bromodomain
17天前
已完结
CCS1477: A Novel Small Molecule Inhibitor of p300/CBP Bromodomain for the Treatment of Acute Myeloid Leukaemia and Multiple Myeloma
17天前
已关闭
The EP300-Targeting Drug CCS1477 Inhibits the Growth and Development ofDiffuse Large B-Cell Lymphoma by Promoting Apoptosis and Mitophagy to ReduceDrug Resistance
17天前
已完结
P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML
17天前
已关闭
Therapeutic targeting of the p300/CBP bromodomain enhances the efficacy of immune checkpoint blockade therapy
17天前
已完结
皖公网安备34019202002308
